Latest Content

David Coman, CEO, BGBx, explains how the firm's rebranding reflects a broader shift in biopharma commercialization, where integrating consulting, communications, and a three-dimensional science framework is increasingly necessary for companies.

State-level access pathways won't cannibalize clinical trials for patients. Instead they could solve biotech's in-human data catch-22, and restore patient trust along the way.

In today's Pharmaceutical Executive Daily, Roche and Nurix Therapeutics announce a global collaboration, a pharma M&A roundup covers three deals announced today, and Pharmaceutical Executive contributors examine how an emerging wave of biologics is signaling a new treatment era in alopecia areata beyond the established JAK inhibitor class.

Incyte, Galmed Pharmaceuticals, and Johnson & Johnson each announced acquisitions this week, with deals spanning a $2 billion bet on a Phase III bleeding disorder antibody, a GI medtech pivot, and a $1 billion move into KRAS-targeting degrader conjugates as dealmaking across therapeutic categories continues.

Roche has struck an exclusive collaboration with Nurix Therapeutics to co-develop BTK degrader bexobrutideg, paying over $700 million upfront in a deal that could top $3 billion in total.

Driven by rising prevalence and awareness of aesthetic appeal and self-image, the Alopecia Areata market is poised for steady growth.

In today's Pharmaceutical Executive Daily, the Supreme Court unanimously rules in favor of Hikma Pharmaceuticals in its patent dispute with Amarin over Vascepa, Pfizer licenses Chai Discovery's generative AI platform, and C.K. Wang argues that high-quality real-world data represents the most promising path forward for closing persistent gaps in ovarian cancer care.

The Supreme Court ruled unanimously in favor of Hikma Pharmaceuticals, finding its generic Vascepa did not infringe Amarin's patents under the skinny-label pathway, a decision that strengthens legal protections for generic manufacturers.

Chai Discovery has licensed its generative AI drug discovery platform to Pfizer, giving the company early access to its next-generation Chai-3 model and a custom model trained on Pfizer's own data.

In today's Pharmaceutical Executive Daily, Eli Lilly escalates its 340B enforcement standoff by notifying covered entities of a five-business-day window to submit required claims data or lose access to 340B pricing, Alnylam Pharmaceuticals and Inceptive Nucleics announce a three-year strategic AI collaboration worth up to $2 billion, and Anne Marie Robertson of Eversana speaks on the trends shaping the future of oncology commercialization following ASCO 2026.

Alnylam Pharmaceuticals has partnered with Inceptive to apply generative AI to siRNA design, pairing Inceptive's biology-trained models with Alnylam's two decades of proprietary RNAi data to accelerate candidate discovery.

Model N Senior Vice President Jesse Mendelsohn explores the hidden costs and realities of PBM-driven drug pricing and the growing challenges manufacturers face in ensuring contract compliance, formulary access and reimbursement accuracy.

Robertson discusses the trends shaping the future of oncology commercialization.